3SBio (TRSBF) AI Stock Analysis

21 Followers

3SBio

(Other OTC:TRSBF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthThe sharp 2025 revenue acceleration indicates substantially stronger commercial traction across 3SBio’s marketed therapies. If maintained, this broader sales base can support operating leverage, fund product development, and strengthen the company’s position in its focused biopharmaceutical markets.

Negative Factors

Earnings DurabilityThe strong 2025 results have not yet established a consistently repeatable earnings pattern, because key profitability and return measures varied materially in earlier years. Such volatility makes future performance more dependent on whether the latest operating improvement can be sustained.

3SBio (TRSBF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.30B
Dividend Yield: 1.77%
Average Volume (3M): 8,753
Price to Earnings (P/E): 3.8
Beta (1Y): -1.76
Revenue Growth: 101.32%
EPS Growth: 248.51%
Country: US
Employees: 6,068
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

3SBio Business Overview & Revenue Model

Company Description

Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfol...

3SBio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TRSBF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2269	79Outperform	HKD 204.30B	34.83	10.51%	―	21.93%	21.94%
HK:9995	66Neutral	HKD 56.21B	8.51	105.60%	―	292.84%	―
HK:2696	65Neutral	HKD 27.35B	26.69	20.41%	―	32.63%	8.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:9926	48Neutral	HKD 83.86B	-70.81	-10.86%	―	42.47%	-15.80%
HK:1877	41Neutral	HKD 32.01B	-73.23	-7.23%	―	35.82%	54.40%

* Healthcare Sector Average

Performance Comparison

TRSBF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TRSBF	3SBio, Inc.	1.76	-1.82	-50.75%
HK:2269	Wuxi Biologics (Cayman)	48.88	14.40	41.76%
HK:9926	Akeso, Inc.	88.60	-32.90	-27.08%
HK:9995	RemeGen Co. Ltd. Class H	69.95	-14.55	-17.22%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.67	-10.63	-40.42%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.88	-14.87	-22.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

3SBio AI Stock Analysis